Cargando…

Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond?

OBJECTIVE: To evaluate disease activity in patients with relapsing-remitting MS (RRMS) receiving rituximab with an extended dosing interval. METHODS: In the context of COVID-19 pandemic, this was an interim analysis of an ongoing prospective observational study of patients who were stable on rituxim...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maarouf, Adil, Rico, Audrey, Boutiere, Clemence, Perriguey, Marine, Demortiere, Sarah, Pelletier, Jean, Audoin, Bertrand
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7357416/ https://www.ncbi.nlm.nih.gov/pubmed/32587103 http://dx.doi.org/10.1212/NXI.0000000000000825

Ejemplares similares

Hypogammaglobulinemia and Infections in Patients With Multiple Sclerosis Treated With Rituximab
por: Perriguey, Marine, et al.
Publicado: (2021)

Efficacy of Rituximab Outlasts B-Cell Repopulation in Multiple Sclerosis: Time to Rethink Dosing?
por: Claverie, Roxane, et al.
Publicado: (2023)

Disease Evolution in Women With Highly Active MS Who Suspended Natalizumab During Pregnancy vs Rituximab/Ocrelizumab Before Conception
por: Demortiere, Sarah, et al.
Publicado: (2023)

Rituximab-Induced Hypogammaglobulinemia and Infections in AQP4 and MOG Antibody–Associated Diseases
por: Avouac, Alexandre, et al.
Publicado: (2021)

Determining the best window for BNT162b2 mRNA vaccination for SARS-CoV-2 in patients with multiple sclerosis receiving anti-CD20 therapy
por: Rico, Audrey, et al.
Publicado: (2021)

Pure Relapsing Short Myelitis: Part of the Multiple Sclerosis Spectrum or New Entity?
por: Poullet, Zélia, et al.
Publicado: (2022)

TNF-α inhibitors used as steroid-sparing maintenance monotherapy in parenchymal CNS sarcoidosis
por: Hilezian, Frédéric, et al.
Publicado: (2021)

Pharmacodynamics of natalizumab extended interval dosing in MS
por: Zhovtis Ryerson, Lana, et al.
Publicado: (2020)

High levels of serum soluble TWEAK are associated with neuroinflammation during multiple sclerosis
por: Maarouf, Adil, et al.
Publicado: (2019)

Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing
por: Ryerson, Lana Zhovtis, et al.
Publicado: (2019)

Sustained Low Relapse Rate With Highly Variable B-Cell Repopulation Dynamics With Extended Rituximab Dosing Intervals in Multiple Sclerosis
por: Starvaggi Cucuzza, Chiara, et al.
Publicado: (2022)

Rituximab, MS, and pregnancy
por: Smith, Jessica B., et al.
Publicado: (2020)

Extended-Interval Gentamicin Dosing for Pulmonic Tularemia
por: Dietrich, Tyson, et al.
Publicado: (2019)

Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic
por: Zanghì, Aurora, et al.
Publicado: (2022)

Risk factors associated with progression from papilloedema to optic atrophy: results from a cohort of 113 patients
por: Attia, Ruben, et al.
Publicado: (2023)

Cognitive performance shows domain specific associations with regional cortical thickness in multiple sclerosis
por: Stellmann, Jan-Patrick, et al.
Publicado: (2021)

Low-dose rituximab should be used for treating MS in resource-limited settings: No
por: Mateen, Farrah J
Publicado: (2022)

Rituximab resistance in ITP and beyond
por: Xiao, Zhengrui, et al.
Publicado: (2023)

Extending the diabetic retinopathy screening interval beyond 1 year: systematic review
por: Taylor-Phillips, Sian, et al.
Publicado: (2016)

Evaluation of Extended Interval Dosing Aminoglycosides in the Morbidly Obese Population
por: Ross, Ashley L., et al.
Publicado: (2013)

Low-dose rituximab should be used for treating MS in resource-limited settings: Yes
por: Piehl, Fredrik, et al.
Publicado: (2022)

Evaluation of risk of nephrotoxicity with high dose, extended-interval colistin administration
por: Dewan, Arun, et al.
Publicado: (2014)

Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegaly
por: Bernabéu, Ignacio, et al.
Publicado: (2020)

Extended-Interval Dosing of Rezafungin against Azole-Resistant Aspergillus fumigatus
por: Wiederhold, Nathan P., et al.
Publicado: (2019)

Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19
por: Rolfes, Leoni, et al.
Publicado: (2021)

New brain lesions with no impact on physical disability can impact cognition in early multiple sclerosis: A ten-year longitudinal study
por: Wybrecht, D., et al.
Publicado: (2017)

Switch to ocrelizumab in MS patients treated with natalizumab in extended interval dosing at high risk of PML: A 96-week follow-up pilot study
por: Santiago-Setien, Pilar, et al.
Publicado: (2023)

Extended-interval Dosing of Gentamicin for Treatment of Neonatal Sepsis in Developed and Developing Countries
por: Darmstadt, Gary L., et al.
Publicado: (2008)

Real-World Effectiveness of Natalizumab Extended Interval Dosing in a French Cohort
por: Pelle, Juliette, et al.
Publicado: (2023)

Prevalence of Grey Matter Pathology in Early Multiple Sclerosis Assessed by Magnetization Transfer Ratio Imaging
por: Crespy, Lydie, et al.
Publicado: (2011)

Extended-Interval Dosing Strategy of Immune Checkpoint Inhibitors in Lung Cancer: Will it Outlast the COVID-19 Pandemic?
por: Sehgal, Kartik, et al.
Publicado: (2020)

Principles and advances in ultrafast photoacoustics; applications to imaging cell mechanics and to probing cell nanostructure
por: Audoin, Bertrand
Publicado: (2023)

MS/MS-Guided Isolation of Clarinoside, a New Anti-Inflammatory Pentalogin Derivative
por: Audoin, Coralie, et al.
Publicado: (2018)

Extended Interval Dosing Natalizumab and impact on neuropsychological deficits in Relapsing-Remitting Multiple Sclerosis
por: McManus, Eileen J., et al.
Publicado: (2022)

A systematic literature review to evaluate extended dosing intervals in the pharmacological management of acromegaly
por: Fleseriu, M., et al.
Publicado: (2022)

Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study
por: Cantini, Luca, et al.
Publicado: (2023)

Wearing-off symptoms during standard and extended natalizumab dosing intervals: Experiences from the COVID-19 pandemic
por: Bringeland, Gerd Haga, et al.
Publicado: (2021)

Natalizumab wearing-off symptoms: effect of extend interval dosing during Sars-CoV-2 pandemic
por: Magro, Giuseppe, et al.
Publicado: (2022)

Impact of extended interval dosing of immune checkpoint inhibitors in lung cancer patients during the COVID-19 pandemic
por: Veron, Marie, et al.
Publicado: (2023)

Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine
por: Payne, Rebecca P., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8f6au2ei5b6tjsv28omdq78rkj